Quantcast
Last updated on April 18, 2014 at 11:57 EDT

Latest Placebo-controlled study Stories

2014-04-16 00:21:06

TOKYO, April 16, 2014 /PRNewswire/ -- Ajinomoto Pharmaceuticals Co., Ltd. announced on April 16 that the abstract of phase 2a clinical study data of an oral alpha 4 integrin antagonist, development code AJM300, has been accepted for presentation at the Digestive Disease Week 2014 (May 3 - 6 in Chicago, USA). The contents of data will be presented at the beginning of Joint Presidential Plenary Session collaborated by the American Society for Gastrointestinal Endoscopy and the American...

2014-04-11 00:21:52

-SVR(12) rates of 96 percent were achieved in both SAPPHIRE-I (new to therapy) and SAPPHIRE-II (treatment-experienced with pegylated interferon and ribavirin) in adult patients with genotype 1 chronic hepatitis C virus infection LONDON, April 11, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that detailed results from its phase III pivotal study, SAPPHIRE-I, will be presented today at the International Liver Congress(TM) (ILC) 2014 and featured in the ILC press conference....

2014-03-11 23:33:04

Achieve is conducting a phase II, placebo-controlled, multi dose, 24-week clinical study to evaluate the efficacy and safety of a new autoimmune medication in participants living with systemic lupus erythematosus (SLE). Birmingham, Alabama (PRWEB) March 11, 2014 *To see if you qualify for this Lupus Clinical Trial in Birmingham, visit Achieve Clinical Research on the web (http://www.achieveclinical.com/) or contact us directly at (205) 380-6434. There is no cost to participate, no...

2014-02-25 08:31:00

- Study Meets Primary and Both Key Secondary Endpoints - BRISBANE, Calif., Feb. 25, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that top-line data from ASCEND, a Phase 3 trial evaluating pirfenidone in patients with idiopathic pulmonary fibrosis (IPF), demonstrated that pirfenidone significantly reduced IPF disease progression as measured by change in percent predicted forced vital capacity (FVC) from Baseline to Week 52 (rank ANCOVA p<0.000001)....

2014-02-13 23:26:10

RE-BODY® Launches RE-BODY Fruit & Flower Slimming Formula™ with Meratrim® Gainesville, Fla (PRWEB) February 13, 2014 RE-BODY®, a market leader in healthy weight management supplements, has launched RE-BODY Fruit & Flower Slimming Formula™ with Meratrim®, the newest addition to the brand’s already dynamic product line. RE-BODY Fruit & Flower Slimming Formula is non-stimulant and features pure Meratrim, a blend of plant extracts derived from...

2014-02-11 23:28:04

Achieve is conducting a placebo-controlled, multicenter study to evaluate the blood pressure reduction with ambulatory blood pressure monitoring (ABPM), safety, and tolerability of a new drug in the treatment of subjects with hypertension and type 2 diabetes mellitus. Birmingham, AL (PRWEB) February 11, 2014 Achieve is conducting a placebo-controlled, multicenter study to evaluate the blood pressure reduction with ambulatory blood pressure monitoring (ABPM), safety, and tolerability of a...

2014-01-24 23:21:39

Natreon, Inc, and NutraGenesis, LLC are pleased to announce a new study published on Sensoril® demonstrates Sensoril’s ability to significantly improve cognitive and psychomotor performance. Brattleboro, VT (PRWEB) January 24, 2014 Natreon, Inc, and NutraGenesis, LLC are pleased to announce publication of a new study on Sensoril® which demonstrated Sensoril’s ability to significantly improve cognitive and psychomotor performance during simple reaction, choice discrimination,...

2014-01-09 16:25:37

OPEN-LABEL EXTENSION SHOWS A FAVORABLE SAFETY PROFILE AND DYSKINESIA REDUCTION THROUGH 12 WEEKS OF DOSING SAN DIEGO, Jan. 9, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that NBI-98854, a small molecule VMAT2 inhibitor, in development for tardive dyskinesia, showed an excellent safety profile and a clinically meaningful reduction in tardive dyskinesia symptoms in up to twelve weeks of continuous dosing. This is the second study reporting out this...

2014-01-06 16:27:45

Plans to submit end of phase II meeting request to FDA SAN DIEGO, Jan. 6, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that NBI-98854, a small molecule VMAT2 inhibitor, showed a statistically significant and clinically meaningful reduction in tardive dyskinesia symptoms in the Phase IIb Kinect 2 study. The pre-specified primary endpoint was the change-from-baseline in the Abnormal Involuntary Movement Scale (AIMS) at Week 6 as assessed by central...

2013-12-09 08:30:31

Efficacy and Safety/Tolerability Findings Presented at 2013 American Epilepsy Society Annual Meeting MAPLE GROVE, Minn., Dec. 9, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith) today presented results from its global Phase 3 (PREVAIL) study of USL255 (extended-release topiramate), showing that the investigational drug met its primary and secondary endpoints for efficacy and demonstrated favorable safety and tolerability in epilepsy patients with refractory partial-onset...